Featured Publications
Association of renalase with clinical outcomes in hospitalized patients with COVID-19
Safdar B, Wang M, Guo X, Cha C, Chun HJ, Deng Y, Dziura J, El-Khoury JM, Gorelick F, Ko AI, Lee AI, Safirstein R, Simonov M, Zhou B, Desir GV. Association of renalase with clinical outcomes in hospitalized patients with COVID-19. PLOS ONE 2022, 17: e0264178. PMID: 35259186, PMCID: PMC8903289, DOI: 10.1371/journal.pone.0264178.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsRenalase levelsIntensive care unit admissionHospitalized COVID-19 patientsMean age 64 yearsCOVID-19Cox proportional hazards modelCare unit admissionPrimary composite outcomeRetrospective cohort studyUse of vasopressorsSevere COVID-19IL-6 levelsAge 64 yearsRisk of deathCOVID-19 subjectsInitial disease severityProportional hazards modelCOVID-19 diseasePlasma renalaseUnit admissionICU admissionCohort studyComposite outcomeCytokine levels
2024
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024
DeCuir J, Payne A, Self W, Rowley E, Dascomb K, DeSilva M, Irving S, Grannis S, Ong T, Klein N, Weber Z, Reese S, Ball S, Barron M, Naleway A, Dixon B, Essien I, Bride D, Natarajan K, Fireman B, Shah A, Okwuazi E, Wiegand R, Zhu Y, Lauring A, Martin E, Gaglani M, Peltan I, Brown S, Ginde A, Mohr N, Gibbs K, Hager D, Prekker M, Mohamed A, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Chang S, Mallow C, Kwon J, Exline M, Columbus C, Vaughn I, Safdar B, Mosier J, Harris E, Casey J, Chappell J, Grijalva C, Swan S, Johnson C, Lewis N, Ellington S, Adams K, Tenforde M, Paden C, Dawood F, Fleming-Dutra K, Surie D, Link-Gelles R, Collaborators C, Collaborators C, Ghamande S, Gottlieb R, McNeal T, Raver C, Bender W, Fletcher L, Heaton P, Kane S, McEvoy C, Thapa S, Vazquez-Benitez G, Frosch A, Lamerato L, Ramesh M, Arnofer J, Ali H, Hopkins J, Crane B, Dandamudi P, Goddard K, Hansen J, Timbol J, Zerbo O, Allen K, Duszynski T, Fadel W, Rogerson C, Qadir N, Chavez C, Doyle B, Mayer D, Rao S, Rivas C, Johnson N, Baughman A, Lwin C, Rhoads J, Womack K, Dunne M, Ciesla A, Mak J, Najdowski M, Ray C. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024. MMWR Morbidity And Mortality Weekly Report 2024, 73: 180-188. PMID: 38421945, PMCID: PMC10907041, DOI: 10.15585/mmwr.mm7308a5.Peer-Reviewed Original ResearchConceptsVaccine effectivenessEmergency departmentCOVID-19 vaccineCDC's Advisory CommitteeCOVID-19-associated hospitalizationUrgent careCOVID-19 vaccine dosesImmunocompetent adultsMedian intervalCase-control designVE estimatesVaccine doseImmunization PracticesTest-negativeSevere diseaseCDC recommendationsDoseVaccineHospitalVE networkCOVID-19CDCMonthsAdvisory CommitteeDays
2023
1108. Severity of Illness among Adults Hospitalized with Respiratory Syncytial Virus Compared with COVID-19 and Influenza — IVY Network, 25 Hospitals, 20 U.S. States, January 31, 2022 – April 11, 2023
Yuengling K, Surie D, DeCuir J, Zhu Y, Gaglani M, Ginde A, Gibbs K, Prekker M, Mohamed A, Johnson N, Peltan I, Bender W, Mallow C, Kwon J, Lauring A, Columbus C, Vaughn I, Safdar B, Chappell J, Baughman A, Swan S, Johnson C, McMorrow M, Self W, Martin E. 1108. Severity of Illness among Adults Hospitalized with Respiratory Syncytial Virus Compared with COVID-19 and Influenza — IVY Network, 25 Hospitals, 20 U.S. States, January 31, 2022 – April 11, 2023. Open Forum Infectious Diseases 2023, 10: ofad500.081. PMCID: PMC10678102, DOI: 10.1093/ofid/ofad500.081.Peer-Reviewed Original ResearchInvasive mechanical ventilationAcute respiratory illnessAdvanced respiratory supportSARS-CoV-2Respiratory supportRespiratory illnessCOVID-19Use of IMVHigh-flow nasal cannulaMultivariable logistic regression modelAsahi Kasei PharmaMedical condition categoriesSeverity of RSVFlow nasal cannulaInfluenza-associated hospitalizationsNon-invasive ventilationShortness of breathSeverity of illnessRespiratory syncytial virusSevere respiratory illnessGrant/research supportChi-square testLogistic regression modelsPrevalence of RSVMedian ageDisease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023
Surie D, Yuengling K, DeCuir J, Zhu Y, Gaglani M, Ginde A, Talbot H, Casey J, Mohr N, Ghamande S, Gibbs K, Files D, Hager D, Ali H, Prekker M, Gong M, Mohamed A, Johnson N, Steingrub J, Peltan I, Brown S, Leis A, Khan A, Hough C, Bender W, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Lauring A, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Halasa N, Chappell J, Grijalva C, Baughman A, Rice T, Womack K, Han J, Swan S, Mukherjee I, Lewis N, Ellington S, McMorrow M, Martin E, Self W, Network I. Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 1083-1088. PMID: 37796753, PMCID: PMC10564326, DOI: 10.15585/mmwr.mm7240a2.Peer-Reviewed Original ResearchConceptsHigh-flow nasal cannulaInvasive mechanical ventilationRSV disease severityNoninvasive ventilationDisease severityCOVID-19Intensive care unit admissionRespiratory syncytial virus vaccinationOlder adultsLaboratory-confirmed RSVCare unit admissionAcute respiratory illnessFlow oxygen therapyMultivariable logistic regressionCDC's Advisory CommitteeRespiratory syncytial virusSARS-CoV-2Advisory CommitteeUnit admissionICU admissionImmunization PracticesRSV vaccinationVirus vaccinationAdults AgedInfluenza severityRenin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19
Self W, Shotwell M, Gibbs K, de Wit M, Files D, Harkins M, Hudock K, Merck L, Moskowitz A, Apodaca K, Barksdale A, Safdar B, Javaheri A, Sturek J, Schrager H, Iovine N, Tiffany B, Douglas I, Levitt J, Busse L, Ginde A, Brown S, Hager D, Boyle K, Duggal A, Khan A, Lanspa M, Chen P, Puskarich M, Vonderhaar D, Venkateshaiah L, Gentile N, Rosenberg Y, Troendle J, Bistran-Hall A, DeClercq J, Lavieri R, Joly M, Orr M, Pulley J, Rice T, Schildcrout J, Semler M, Wang L, Bernard G, Collins S, Becker R, del Zoppo G, Henke P, Holubkov R, Johnson M, Kerr K, Lipman H, Lurie F, Pitt B, Vesely S, Fleg J, Aamodt D, Ayers J, Clark D, Collins J, Cook M, Dixon S, Graves J, Jordan C, Lindsell C, Lopez I, McKeel D, Orozco D, Prato N, Qi A, Qutab M, Stoughton C, Vermillion K, Walsh K, Winchell S, Young T, Franklin R, Wagner E, Walther T, Demitrack M, Johnson J, Walsh R, Bales B, Miller K, Torr D, Barot H, Landreth L, LaRose M, Parks L, Teixeira J, Cardenas S, Ceniceros J, Cunningham A, Kunkel S, Lovato D, Zimmerman B, Nguyen T, Zeger W, Nichols H, Wiedel N, Javaheri A, Stilinovic S, Brokowski C, Lu J, Solberg M, Lee D, Roach K, Tiffany B, Tanner C, Taylor A, Zumbahl J, Syed A, Mason J, Jackson P, Coleman R, Haughey H, Cherabuddi K, James N, Wakeman R, Duncan C, Montero C, Rogers A, Wilson J, Vojnik R, Perez C, Wyles D, Hiller T, Oakes J, Garcia A, Gong M, Mohamed A, Andrea L, Nair R, Nkemdirim W, Lopez B, Boujid S, Torres M, Garcia O, Martinez F, Baduashvili A, Bastman J, Chauhan L, Douin D, Finck L, Licursi A, ten Lohuis C, Zhang S, Bender W, Tovar S, Hayes S, Kurtzman N, Rosseto E, Scaffidi D, Shapiro N, Pak J, Allada G, Briceno G, Peña J, Oh M, Ali H, Beselman S, Eby Y, Klimov V, Hite R, Tanzeem H, Droege C, Winter J, Jackman S, Caudill A, Bayoumi E, Pascual E, Chen P, Mucha S, Thiruchelvam N, Siuba M, Mehkri O, Driver B, Hendrickson A, Kaus O, Ontiveros C, Riehm A, Laudun S, Hudock D, Ensley C, Shaner V, Gentile N, Isenberg D, Reimer H, Cincola P, Harris E, Callahan S, Yamane M, Barrios M, Desai N, Bharara A, Keller M, Majumder P, Dohe C, D’Armiento J, Goldklang M, Wagener G, Fonseca L, Valezquez-Sanchez I, Johnson N, Petersen E, Fuentes M, Newton M, Gundel S, Srinivasan V, Steel T, Robinson B. Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19. JAMA 2023, 329: 1170-1182. PMID: 37039791, PMCID: PMC10091180, DOI: 10.1001/jama.2023.3546.Peer-Reviewed Original ResearchConceptsAngiotensin II type 1 receptorII type 1 receptorRenin-angiotensin systemSevere COVID-19Type 1 receptorCause mortalityRAS agentsRAS modulationPlacebo groupAngiotensin IIIntravenous infusionOdds ratioSafety outcomesCOVID-19Renin-angiotensin system modulationSARS-CoV-2 infectionAcute COVID-19Key secondary outcomesAction of angiotensinKidney replacement therapySupplemental oxygen useCOVID-19 pathophysiologyContinuous intravenous infusionLast followSecondary outcomes
2020
Unique Risks and Solutions for Equitable Advancement during the Covid-19 Pandemic: Early Experience from Frontline Physicians in Academic Medicine
Madsen T, Dobiesz V, Das D, Sethuraman K, Agrawal P, Zeidan A, Goldberg E, Safdar B, Lall M. Unique Risks and Solutions for Equitable Advancement during the Covid-19 Pandemic: Early Experience from Frontline Physicians in Academic Medicine. NEJM Catalyst 2020 PMCID: PMC7380702, DOI: 10.1056/cat.20.0268.Peer-Reviewed Original Research